CCL2 and type 2 diabetes mellitus: Vildagliptin treatment inhibited the increase in AGEs, RAGE and oxidative stress marker, 8-hydroxydeoxyguanosine levels of thoracic aorta of obese and type 2 diabetic rats, which were in association with decreased gene expression of MCP-1, VCAM-1 and PAI-1 and suppressed activity of NF-κB [95].